Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial.
Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S. Murai K, et al. Among authors: kondo t. Lancet Haematol. 2021 Dec;8(12):e902-e911. doi: 10.1016/S2352-3026(21)00333-1. Lancet Haematol. 2021. PMID: 34826413 Clinical Trial.
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.
Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K. Takahashi N, et al. Among authors: kondo t. Biomark Res. 2014 Mar 20;2(1):6. doi: 10.1186/2050-7771-2-6. Biomark Res. 2014. PMID: 24650752 Free PMC article.
Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Ishida Y, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Ogawa K, Nagashima T, Sato S, Watanabe R, Yamamoto S, Hirose T, Saitou S, Yonezumi M, Kondo T, Kato Y, Mochizuki N, Ohno K, Kishino S, Kubo K, Oyake T, Ito S; Inter-Michinoku Dasatinib Study Group (IMIDAS). Ishida Y, et al. Among authors: kondo t. Eur J Clin Pharmacol. 2016 Feb;72(2):185-93. doi: 10.1007/s00228-015-1968-y. Epub 2015 Oct 27. Eur J Clin Pharmacol. 2016. PMID: 26507546 Clinical Trial.
Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
Kondo T, Nagamura-Inoue T, Tojo A, Nagamura F, Uchida N, Nakamae H, Fukuda T, Mori T, Yano S, Kurokawa M, Ueno H, Kanamori H, Hashimoto H, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Ohashi K. Kondo T, et al. Am J Hematol. 2017 Sep;92(9):902-908. doi: 10.1002/ajh.24793. Epub 2017 Jun 9. Am J Hematol. 2017. PMID: 28543934 Free article. Clinical Trial.
Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K, Yamaguchi K, Ito S, Miyagishima T, Shindo M, Wakasa K, Inomata M, Nagashima T, Kondo T, Fujimoto N, Yamamoto S, Yonezumi M, Oyake T, Kowata S, Tsukushi Y, Mine T, Meguro K, Ikeda K, Watanabe R, Saito S, Sato S, Tajima K, Chou T, Kubo K, Oba K, Sakamoto J, Ishida Y; The Inter-Michinoku Dasatinib Study Group (IMIDAS). Murai K, et al. Among authors: kondo t. Eur J Haematol. 2018 Jan;100(1):27-35. doi: 10.1111/ejh.12969. Epub 2017 Oct 16. Eur J Haematol. 2018. PMID: 28895203 Clinical Trial.
Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S, Matsukawa T, Yamamoto S, Ito S, Shindo M, Sato K, Kondo T, Kohda K, Sakai H, Mori A, Takahashi T, Ikeda H, Kuroda H, Haseyama Y, Yamamoto M, Sarashina T, Yoshida M, Kobayashi R, Nishio M, Ishihara T, Hirayama Y, Kakinoki Y, Kobayashi H, Fukuhara T, Imamura M, Kurosawa M. Ota S, et al. Among authors: kondo t. Eur J Haematol. 2018 Jul;101(1):95-105. doi: 10.1111/ejh.13081. Epub 2018 May 23. Eur J Haematol. 2018. PMID: 29660177
Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group. Noguchi S, et al. Int J Hematol. 2018 Aug;108(2):176-183. doi: 10.1007/s12185-018-2459-6. Epub 2018 Apr 30. Int J Hematol. 2018. PMID: 29713954 Clinical Trial.
Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib.
Kondo T, Fujioka M, Tsuda M, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Nagashima T, Wakasa K, Fujimoto N, Yamamoto S, Yonezumi M, Saito S, Sato S, Ogawa K, Chou T, Watanabe R, Kato Y, Takahashi S, Okano Y, Yamamoto J, Ohta M, Iijima H, Oba K, Kishino S, Sakamoto J, Ishida Y, Ohba Y, Teshima T; Inter-Michinoku Dasatinib Study Group (IMIDAS). Kondo T, et al. Cancer Sci. 2018 Jul;109(7):2256-2265. doi: 10.1111/cas.13625. Epub 2018 May 29. Cancer Sci. 2018. PMID: 29719934 Free PMC article. Clinical Trial.
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S. Fujisawa S, et al. Among authors: kondo t, kondo e. Int J Clin Oncol. 2019 Apr;24(4):445-453. doi: 10.1007/s10147-018-1368-2. Epub 2018 Nov 12. Int J Clin Oncol. 2019. PMID: 30421023 Free PMC article. Clinical Trial.
Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.
Kondo T, Fujioka M, Fujisawa S, Sato K, Tsuda M, Miyagishima T, Mori A, Iwasaki H, Kakinoki Y, Yamamoto S, Haseyama Y, Ando S, Shindo M, Ota S, Kurosawa M, Ohba Y, Teshima T; North Japan Hematology Study Group (NJHSG). Kondo T, et al. Int J Hematol. 2019 Oct;110(4):482-489. doi: 10.1007/s12185-019-02696-w. Epub 2019 Jun 25. Int J Hematol. 2019. PMID: 31240558 Clinical Trial.
7,784 results